CLINICAL ADVANTAGES OF TELMISARTAN: FEATURES OF PHARMACOKINETICS, PHARMACODYNAMICS AND EFFECTS ON THE DAILY BLOOD PRESSURE PROFILE
https://doi.org/10.20996/1819-6446-2017-13-4-550-557
Abstract
The features of the pharmacokinetics of the angiotensin II receptor blocker telmisartan are considered. Thanks to these features it has a number of advantages in comparison with other angiotensin II receptor blockers and antihypertensive drugs from other classes. Particular attention is paid to the long half-life of telmisartan, which retains its effect for more than 24 hours. This is especially important for controlling blood pressure (BP) in the early morning hours. Data from studies demonstrating that excessive BP rises in the early morning hours increase the risk of cardiovascular and cerebrovascular complications are presented. The results of comparative studies of telmisartan using the ambulatory BP monitoring, which testify to its advantages in BP control within 24-hours, are considered.
About the Authors
O. D. Ostroumova
A.I. Evdokimov Moscow State University of Medicine and Dentistry;
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
MD, PhD, Professor, Chair of Faculty Therapy and Occupational Diseases, Delegatskaya ul. 20-1, Moscow, 127473;
Chair of Clinical Pharmacology and Propaedeutics of Internal Diseases, Trubetskaya ul. 8-2, Moscow, 119991
E. A. Smolyarchuk
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
MD, PhD, Associate Professor, Chair of Clinical Pharmacology and Propaedeutics of Internal Diseases,
Trubetskaya ul. 8-2, Moscow, 119991
O. V. Bondarec
A.I. Evdokimov Moscow State University of Medicine and Dentistry
Russian Federation
Russian Federation
MD, PhD, Associate Professor, Chair of Faculty Therapy and Occupational Diseases,
Delegatskaya ul. 20-1, Moscow, 127473
E. E. Paleeva
A.I. Evdokimov Moscow State University of Medicine and Dentistry
Russian Federation
Russian Federation
MD, PhD, Assistant, Chair of Faculty Therapy and Occupational Diseases,
Delegatskaya ul. 20-1, Moscow, 127473
References
1. Diagnostics and treatment of arterial hypertension (Clinical Guidelines). Kardiologicheskij Vestnik. 2015;X(1):3-30. (In Russ.) [Диагностика и лечение артериальной гипертонии: клинические рекомендации. Кардиологический Вестник. 2015;X(1):3-30].
2. Mancia G., Fagard R., Narkiewicz K., et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Hypertens J. 2013;31: 1281-357.
3. Kukes V.G., Sychev D.A., eds. Clinical Pharmacology. Moscow: GEOTAR-Media; 2015. (In Russ.) [Кукес В.Г., Сычев Д.А., ред. Клиническая фармакология. М.: ГЭОТАР-Медиа; 2015].
4. Wienen W., Hauel N., van Meel J.C.A., et al. Pharmacological characterization of the novel nonpeptide angiotensinII receptor antagonist. Br J Pharmacol. 1993;110 (1):245-52.
5. Kakuta H., Sudoh K., Sasamata M., Yamagishi S. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: Comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res. 2005;25:41-6.
6. White W.B. Relevance of blood pressure variation in the circadian onset of cardiovascular events. J Hypertens. 2003;21 (Suppl 6):S9-S15.
7. Peixoto A.J., White W.B. Circadian blood pressure: clinical implications based on the pathophysiology of its variability. Kidney Int. 2007;71(9):855-60.
8. Willich S.N. Circadian variation and triggering of cardiovascular events. Vasc Med. 1999;4:41-9.
9. Argentino C., Toni D., Rasura M., et al. Circadian variation in the frequency of ischemic stroke. Stroke. 1990;21:387-9.
10. Willich S.N., Levy D., Rocco M.B., et al. Circadian variation in the incidence of sudden cardiac death in the Framingham Heart Study population. Am J Cardiol. 1987;60:801-6.
11. Weber M.A., Fodera S.M. Circadian variations in cardiovascular disease: chronotherapeutic approaches to the management of hypertension. Rev Cardiovasc Med. 2004;5:148-55.
12. Willich S.N., Lewis M., Lowel H., et al. Physical exertion as a trigger of acute myocardial infarction. N Engl J Med. 1993;329:1684-90.
13. Elliott W.J. Circadian variation in the timing of stroke onset. А meta-analysis. Stroke. 1998;29: 992-6.
14. Kario K., Shimada K., Pickering T.G. Clinical implication of morning blood pressure surge in hypertension. J Cardiovasc Pharmacol. 2003;42Suppl 1:S87-91.
15. Kario К., Pickering Т. G., Umeda Y., et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives. A prospective study. Circulation. 2003;107:1401-6.
16. Shevchenko O. P., Prassonisi E.A., Yakhno N. N., Parfenov V.A.Arterial hypertension and cerebral stroke. Moscow: Reaffirm; 2001. (In Russ.) [Шевченко О.П., Праскурничий Е.А., Яхно Н.Н., Парфенов В.А. Артериальная гипертония и церебральный инсульт. М: Реафарм; 2001].
17. Slergiou G.S., Vemmos K.N., Pliarchopoulou K.M., et al. Parallel moning and evening surge in stroke onset, blood pressure, and physical activity. Stroke. 2002;33:1480-6.
18. RedЧn J., Roca-Cusachs A., Mora-Macia J. Uncontrolled early morning blood pressure in medicated patients: the ACAMPA study. Blood Press Monit. 2002;7:111-6.
19. Kario K., Eguchi K., Umeda Y., et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives. Circulation. 2003;108:72e-73e.
20. Kaplan N.M. Morning surge in blood pressure. Circulation. 2003; 107:1347.
21. Hoshide S., Kario K., de la Sierra A. et al. Ethnic differences in the degree of morning blood pressure surge and in its determinants between Japanese and European hypertensive subjects data from the ARTEMIS Study. Hypertension. 2015;66(4):750-6
22. Brandenberger G., Follenius M., Goichot B., et al. Twenty-four-profiles of plasma rennin activity in relation to the sleep-wake cycle. J Hypertens. 1994;12:277-83.
23. Lacourcière Y., NeutelJ.M.,Davidai G., Koval S.A multicenter, 14-week study oftelmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring. Am J Hypertens. 2006;19:104-12.
24. Williams B., LacourciПre Y., Schumacher H., et al. Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials. J Hum Hypertens. 2009;23(9):610-9.
25. Fogari R., Mugellini A., Zoppi A., et al. Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. J Hum Hypertens. 2006;20(3):177-85.
26. SmithD.H.G., NeutelJ.M., Morgenstern P. Once-daily telmisartan compared with enalapril in the treatment of hypertension. Adv Ther. 1998;15:229-40.
27. Nalbantgil I., Nalbantgil S., Ozerkan F., et al. The efficacy of telmisartan compared with perindopril in patients with mild-to-moderate hypertension. Int J Clin Pract. 2004;58:50-4.
28. Neutel J.M., Smith D.H.G. Evaluation of angiotensin II receptor blockers for 24-hour blood pressure control: meta-analysis of a clinical database. J Clin Hypertens. 2003;5:58-63.
29. Sharma A., Davidson J., Koval S., Lacourcière Y. Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study. Cardiovasc Diabetol. 2007;6:28-36.
30. Neutel J.M., Littlejohn T.W., Chrysant S.G., Singh A. Telmisartan Study Group. Telmisartan/hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in managing patients with mildto-moderate hypertension. Hypertens Res. 2005;28:555-63.
31. Mallion J.M., Siche J., Lacourcière Y. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagoniststelmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens. 1999;13:657-64.
32. Ding P.Y., Chu К.М., ChiangН.Т., Shu К.Н. A double-blind ambulatory blood pressure monitoring study of the efficacy and tolerability of once-daily telmisartan 40 mg in comparison with losartan 50 mg in the treatment of mild-to-moderate hypertension in Taiwanese patients. Int J Clin Pract Suppl. 2004;58:16-22.
33. White W.B., Lacourciere Y., Davidai G. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure. Impact on the early morning period. Am J Hypertens. 2004;17:347-53.
34. Lacourcière Y., KrzesinskiJ.M., White W.B., et al. Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Press Monit. 2004;9:203-10.
35. Neldam S., Edwards C. Telmisartan plus hydrochlorothiazide compared with amlodipine plus hydrochlorothiazide in older patients with systolic hypertension: Results from a large ABPM study. Am J Geriat Cardiol. 2006;16:151-60.
36. Lacourcière Y., Lenis J., Orchard R., et al. A comparison of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine. Blood Press Monit. 1998;3:295-302.
37. Galzerano D., Tammaro P., Cerciello A., et al. Freehand three-dimensional echocardiographic assessment of efficacy of telmisartan on left ventricular mass in hypertensive patients: a multicentre study. J Hum Hypertens. 2004;18:53-9.
38. Galzerano D., Tammaro P., Viscovo L., et al. Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study. Am J Hypertens. 2005;18:1563-9.
39. White W.B., Giles T., Bakris G.L., et al. Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring the primary care setting. Am Heart J. 2006;151(1):176-84.
40. Konradi A.O., Polunichev E.V. Inadequate adherence to treatment of arterial hypertension: causes and ways of correction. Arterial'naya Gipertenziya. 2004;10(3):137-43. (In Russ.) [Конради А.О., Полуничева Е.В. Недостаточная приверженность к лечению артериальной гипертензии: причины и пути коррекции. Артериальная Гипертензия. 2004;10(3):137-43].
41. Corrao G., Rea F., Ghirardi A., et al. Adherence with antihypertensive drug therapy and the risk of heart failure in clinical practice. Hypertension. 2015;66(4):742-9.
42. Arshad A.R. Frequency of Poor Adherence to Antihypertensive Treatment and an Analysis of Clinicodemographic Correlates. J Coll Physicians Surgak. 2015;25(12):911-3.
43. Kim S., Shin D.W., Yun J.M., et al. Medication Adherence and the Risk of Cardiovascular Mortality and Hospitalization Among Patients With Newly Prescribed Antihypertensive Medications. Hypertension. 2016;67(3):506-12.
44. Oshchepkova E.V., Isaeva L.G. Low adherence of hypertension patients to treatment: approaches to its improvement. Atmosfere. Kardiologiya. 2003;3:33-6. (In Russ.) [Ощепкова Е. В., Исаева Л.Г. Низкая приверженность больных артериальной гипертонией к лечению: подходы к ее улучшению. Атмосфера. Кардиология. 2003; 3:33-6].
45. Hohlov A.L., Lisenkov L.A., Rakov A.A. Аnalysis of the determinants of adherence to antihypertensive therapy. Kachestvennaya Klinicheskaya Praktika. 2003;4:59-66. (In Russ.) [Хохлов А.Л., Лисенкова Л.А., Раков А.А. Анализ факторов, определяющих приверженность к антигипертензивной терапии. Качественная Клиническая Практика. 2003;4:59-66].
46. TsiantouV., Pantzou P., Pavi E., et al. Factors affecting adherence to antihypertensive medication in Greece: results from a qualitative study. Patient Prefer Adherence. 2010;4:335-43.
47. Dragomir A., Côté R., Roy L., et al. Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs. Med Care. 2010;48(5):418-25.
48. Simpson S.H., Eurich D.T., Majumdar S.R., et al. A meta-analysis of the association between adherence to drug therapy andmortality. BMJ. 2006;333:15.
49. Instructions for use of the medicinal product for medical use Telmisartan. Available at: http://grls.rosminzdrav.ru. Checked by 08/24/2017. (In Russ) [Инструкция по применению лекарственного препарата для медицинского применения Телмисартан. Доступно на: http://grls.rosminzdrav.ru.Проверено 24.08.2017].
50. Maksimov M.L., Dralova O.V. Angiotensin receptor blocker telmisartan: efficacy, safety and relevance of clinical use. Sistemnye Gipertenzii. 2017;14(1):51-7. (In Russ.) [Максимов М.Л., Дралова О.В. Блокатор рецепторов ангиотензина телмисартан: эффективность, безопасность и актуальность клинического применения. Системные Гипертензии. 2017;14(1):51-7].
Review
For citations:
Ostroumova O.D., Smolyarchuk E.A., Bondarec O.V., Paleeva E.E. CLINICAL ADVANTAGES OF TELMISARTAN: FEATURES OF PHARMACOKINETICS, PHARMACODYNAMICS AND EFFECTS ON THE DAILY BLOOD PRESSURE PROFILE. Rational Pharmacotherapy in Cardiology. 2017;13(4):550-557. (In Russ.) https://doi.org/10.20996/1819-6446-2017-13-4-550-557
Views: 4280
Email this article 